Nivolumab Plus Cisplatin/Pemetrexed or Cisplatin/Gemcitabine as Induction in Resectable NSCLC

Authors

C Solomides

Publication/Presentation Date

10-2018

Volume

13

Issue

10

First Page

1028

Last Page

1029

Published In/Presented At

https://doi.org/10.1016/j.jtho.2018.08.1978

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article